SEARCH

SEARCH BY CITATION

References

  • 1
    Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 278799.
  • 2
    Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 116074.
  • 3
    Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008; 26: 174251.
  • 4
    Machiels JP, Subramanian S, Ruzsa A et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomized phase 3 trial. Lancet Oncol 2011; 12: 33343.
  • 5
    Peipp M, Dechant M, Valerius T. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 2008; 20: 43643.
  • 6
    Bibeau F, Lopez-Crapez E, Di Fiore F et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 11229.
  • 7
    Zhang W, Gordon M, Schultheis AM et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25: 37128.
  • 8
    Dechant M, Weisner W, Berger S et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008; 68: 49985003.
  • 9
    Pedersen MW, Jacobsen HJ, Koefoed K et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70: 58897.
  • 10
    Peipp M, Dechant M, Valerius T. Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies. MAbs 2009; 1: 5909.
  • 11
    Lorimer IA. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets 2002; 2: 91102.
  • 12
    Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001; 12: 74560.
  • 13
    Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 47229.
  • 14
    Johns TG, Mellman I, Cartwright GA et al. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. FASEB J 2005; 19: 7802.
  • 15
    Johns TG, Adams TE, Cochran JR et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 2004; 279: 3037584.
  • 16
    Keyt BA, Liu Y, Chen F et al. Human antibody drug conjugates specific to the mutant EGF receptor (EGFRvIII) inhibit tumor growth observed with in vitro and in vivo models of glioma. Proc Amer Assoc Cancer Res 2004; 45: #700 (Abstract).
  • 17
    Dechant M, Vidarsson G, Stockmeyer B et al. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002; 100: 457480.
  • 18
    Beyer T, Lohse S, Berger S, Peipp M, Valerius T, Dechant M. Serum-free production and purification of chimeric IgA antibodies. J Immunol Methods 2009; 346: 2637.
  • 19
    Bendig M, Saldanha J, Kettleborough CA. Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R). Patent EP1362868, 2003.
  • 20
    Old LJ, Johns TG, Panousis C et al. Specific binding proteins and uses thereof. Patent US20090220510, 2009.
  • 21
    Pastan I, Beers R, Chowdhury PS, Bigner D. Anti-egfrvIII scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof. Patent US20030211097, 2003.
  • 22
    Weber R, Feng X, Foord O et al. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof. Patent US20090155282, 2009.
  • 23
    Idusogie EE, Wong PY, Presta LG et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001; 166: 25715.
  • 24
    Bleeker WK, Lammerts van Bueren JJ, van Ojik HH et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004; 173: 4699707.
  • 25
    Jutten B, Dubois L, Li Y et al. Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells. Radiother Oncol 2009; 92: 3938.
  • 26
    Lammerts van Bueren JJ, Bleeker WK, Brannstrom A et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci USA 2008; 105: 610914.
  • 27
    Kuan CT, Wikstrand CJ, Archer G et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer 2000; 88: 9629.
  • 28
    Hadjipanayis CG, Machaidze R, Kaluzova M et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res 2010; 70: 630312.
  • 29
    Ohno M, Natsume A, Ichiro Iwami K et al. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci 2010; 101: 251824.
  • 30
    Jiang H, Wang H, Tan Z et al. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. J Biol Chem 2011; 286: 591320.
  • 31
    Luwor RB, Johns TG, Murone C et al. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 2001; 61: 535561.
  • 32
    Sampson JH, Crotty LE, Lee S et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA 2000; 97: 75038.
  • 33
    Weinstein IB. Cancer. Addiction to oncogenes – the Achilles heal of cancer. Science 2002; 297: 634.
  • 34
    Lutterbuese R, Raum T, Kischel R et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci USA 2010; 107: 1260510.
  • 35
    Peipp M, Schneider-Merck T, Dechant M et al. Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. J Immunol 2008; 180: 433845.
  • 36
    Schlaeth M, Berger S, Derer S et al. Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells. Cancer Sci 2010; 101: 10808.
  • 37
    Schneider-Merck T, Lammerts van Bueren JJ, Berger S et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010; 184: 51220.
  • 38
    Tiroch K, Stockmeyer B, Frank C, Valerius T. Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity. J Immunol 2002; 168: 327582.
  • 39
    Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 78597.
  • 40
    Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2010; 2: 1819.
  • 41
    Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008; 20: 4449.
  • 42
    Hsu YF, Ajona D, Corrales L et al. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Mol Cancer 2010; 9: 139.
  • 43
    Perera RM, Narita Y, Furnari FB et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005; 11: 63909.